Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 18

Results For "platform"

1701 News Found

Transgene and NEC join forces to advance personalized cancer vaccine
R&D | April 08, 2026

Transgene and NEC join forces to advance personalized cancer vaccine

TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor


Solara Active Pharma dispatches final rights share call notice; Rs 112.5 per share due by May 7
News | April 08, 2026

Solara Active Pharma dispatches final rights share call notice; Rs 112.5 per share due by May 7

API maker begins circulation of second and final call money notice for partly paid-up rights shares, completing the last leg of its 2024 fundraising cycle


Trialt and Viedoc team up to transform clinical trials
Clinical Trials | April 08, 2026

Trialt and Viedoc team up to transform clinical trials

The partnership aims to accelerate clinical trial timelines, boost data quality, and improve decision-making for sponsors worldwide


Alpha Cognition secures key US patent for traumatic brain injury treatment
Biopharma | April 08, 2026

Alpha Cognition secures key US patent for traumatic brain injury treatment

The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” strengthens Alpha Cognition’s existing portfolio supporting both ALPHA-1062 and ZUNVEYL


Regeneron and TriNetX forge $200M partnership to supercharge drug discovery and digital health
News | April 08, 2026

Regeneron and TriNetX forge $200M partnership to supercharge drug discovery and digital health

TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners


OneCyte and Kemp Proteins to revolutionize cell line development
Biopharma | April 08, 2026

OneCyte and Kemp Proteins to revolutionize cell line development

Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules


Stipple Bio raises $100M Series A to advance next-gen cancer therapies
Biotech | April 08, 2026

Stipple Bio raises $100M Series A to advance next-gen cancer therapies

The new capital is expected to fund the company through 2029


Biocon launches denosumab biosimilars Bosaya and Aukelso in US market
Biopharma | April 08, 2026

Biocon launches denosumab biosimilars Bosaya and Aukelso in US market

Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market